The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Obesity, Insulin Resistance, and Cardiovascular Disease
Open accessAbstract
The ability of insulin to stimulate glucose disposal varies more than six-fold in apparently healthy individuals. The one third of the population that is most insulin resistant is at greatly increased risk to develop cardiovascular disease (CVD), type 2 diabetes, hypertension, stroke, nonalcoholic fatty liver disease, polycystic ovary disease, and certain forms of cancer. Between 25-35% of the variability in insulin action is related to being overweight. The importance of the adverse effects of excess adiposity is apparent in light of the evidence that more than half of the adult population in the United States is classified as being overweight/obese, as defined by a body mass index greater than 25.0 kg/m(2). The current epidemic of overweight/obesity is most-likely related to a combination of increased caloric intake and decreased energy expenditure. In either instance, the fact that CVD risk is increased as individuals gain weight emphasizes the gravity of the health care dilemma posed by the explosive increase in the prevalence of overweight/obesity in the population at large. Given the enormity of the problem, it is necessary to differentiate between the CVD risk related to obesity per se, as distinct from the fact that the prevalence of insulin resistance and compensatory hyperinsulinemia are increased in overweight/obese individuals. Although the majority of individuals in the general population that can be considered insulin resistant are also overweight/obese, not all overweight/obese persons are insulin resistant. Furthermore, the cluster of abnormalities associated with insulin resistance - namely, glucose intolerance, hyperinsulinemia, dyslipidemia, and elevated plasma C-reactive protein concentrations -- is limited to the subset of overweight/obese individuals that are also insulin resistant. Of greater clinical relevance is the fact that significant improvement in these metabolic abnormalities following weight loss is seen only in the subset of overweight/obese individuals that are also insulin resistant. In view of the large number of overweight/obese subjects at potential risk to be insulin resistant/hyperinsulinemic (and at increased CVD risk), and the difficulty in achieving weight loss, it seems essential to identify those overweight/obese individuals who are also insulin resistant and will benefit the most from weight loss, then target this population for the most-intensive efforts to bring about weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Self-citationRimm, E. B., Stampfer, M. J., Giovannucci, E., Ascherio, A., Spiegelman, D., Colditz, G. A., & Willett, W. C. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117385 · Cited by 843
Are Health Care Professionals Advising Obese Patients to Lose Weight?
Galuska, D. A. (1999) · JAMA · doi:10.1001/jama.282.16.1576 · Cited by 640
Insulin resistance as a predictor of age-related diseases
Facchini, F. S., Hua, N., Abbasi, F., & Reaven, G. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7763 · Cited by 594
Self-citationRelationship between obesity, insulin resistance, and coronary heart disease risk
Abbasi, F., Brown, B. W., Lamendola, C., McLaughlin, T., & Reaven, G. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02051-x · Cited by 573
Self-citationRabinowitz, D., & Zierler, K. L. (1962) · Journal of Clinical Investigation · doi:10.1172/jci104676 · Cited by 521
Olefsky, J., Reaven, G. M., & Farquhar, J. W. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107560 · Cited by 510
Self-citationShen, S.-W., Reaven, G. M., & Farquhar, J. W. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106433 · Cited by 494
Self-citationKuczmarski, R. J., Carroll, M. D., Flegal, K. M., & Troiano, R. P. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00575.x · Cited by 461
IMMUNOASSAY OF ENDOGENOUS PLASMA INSULIN IN MAN
YALOW, R. S., & BERSON, S. A. (1996) · Obesity Research · doi:10.1002/j.1550-8528.1996.tb00274.x · Cited by 460
Differentiation Between Obesity and Insulin Resistance in the Association With C-Reactive Protein
McLaughlin, T., Abbasi, F., Lamendola, C., Liang, L., Reaven, G., Schaaf, P., & Reaven, P. (2002) · Circulation · doi:10.1161/01.cir.0000041046.32962.86 · Cited by 373
Self-citationAssessment of Insulin Resistance with the Insulin Suppression Test and the Euglycemic Clamp
Greenfield, M. S., Doberne, L., Kraemer, F., Tobey, T., & Reaven, G. (1981) · Diabetes · doi:10.2337/diab.30.5.387 · Cited by 366
Self-citationResistance to Insulin-Mediated Glucose Disposal as a Predictor of Cardiovascular Disease
Yip, J. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.8.2773 · Cited by 360
Relationship between degree of obesity and in vivo insulin action in man
Bogardus, C., Lillioja, S., Mott, D. M., Hollenbeck, C., & Reaven, G. (1985) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1985.248.3.e286 · Cited by 344
Self-citationReaven, G. M., Chen, Y. D., Hollenbeck, C. B., Sheu, W. H., Ostrega, D., & Polonsky, K. S. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.1.8421101 · Cited by 214
Self-citationEvaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test
Pei, D., Jones, C. N. O., Bhargava, R., Chen, Y. D. I., & Reaven, G. M. (1994) · Diabetologia · doi:10.1007/bf00404344 · Cited by 209
Self-citationZavaroni, I., Bonini, L., Gasparini, P., Barilli, A. L., Zuccarelli, A., Dall'Aglio, E., Delsignore, R., & Reaven, G. M. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90195-6 · Cited by 206
Self-citationHAVLIK, R. J., HUBERT, H. B., FABSITZ, R. R., & FEINLEIB, M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-855 · Cited by 206
Influence of Nutritional Factors on Prevalence of Diabetes
West, K. M., & Kalbfleisch, J. M. (1971) · Diabetes · doi:10.2337/diab.20.2.99 · Cited by 183
Study of the Relationship Between Glucose and Insulin Responses to an Oral Glucose Load in Man
Reaven, G., & Miller, R. (1968) · Diabetes · doi:10.2337/diab.17.9.560 · Cited by 171
Self-citationKaram, J. H. (1965) · The Lancet · doi:10.1016/s0140-6736(65)91026-3 · Cited by 135
Hollenbeck, C., Chen, Y., & Reaven, G. (1984) · Diabetes · doi:10.2337/diab.33.7.622 · Cited by 116
Self-citationMcLaughlin, T., Abbasi, F., Kim, H.-S., Lamendola, C. A., Schaaf, P., & Reaven, G. M. (2001) · Metabolism · doi:10.1053/meta.2001.24210 · Cited by 87
Self-citationMcLaughlin, T., Abbasi, F., Carantoni, M., Schaaf, P., & Reaven, G. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5441 · Cited by 75
Self-citationUse of Prescription Weight Loss Pills among U.S. Adults in 1996–1998
Khan, L. K., Serdula, M. K., Bowman, B. A., & Williamson, D. F. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00011 · Cited by 63
Abbasi, F., McLaughlin, T., Lamendola, C. A., Lipinska, I., Tofler, G. H., & Reaven, G. M. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.11.2818 · Cited by 52
Self-citationInsulin Resistance, Compensatory Hyperinsulinemia, and Coronary Heart Disease: Syndrome X Revisited
Reaven, G. M. (2001) · Comprehensive physiology · doi:10.1002/cphy.cp070238 · Cited by 38
Self-citation
Cited by
Socransky, S. S., & Haffajee, A. D. (2005) · Periodontology 2000 · doi:10.1111/j.1600-0757.2005.00107.x · Cited by 1,691
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk
Després, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodés-Cabau, J., Bertrand, O. F., & Poirier, P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.159228 · Cited by 1,589
Adiponectin: A Novel Adipokine Linking Adipocytes and Vascular Function
Goldstein, B. J., & Scalia, R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0518 · Cited by 647
Hyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1β Coactivation of SREBP
Lin, J., Yang, R., Tarr, P. T., Wu, P.-H., Handschin, C., Li, S., Yang, W., Pei, L., Uldry, M., Tontonoz, P., et al. (2005) · Cell · doi:10.1016/j.cell.2004.11.043 · Cited by 625
Anti-inflammatory activity of natural dietary flavonoids
Pan, M.-H., Lai, C.-S., & Ho, C.-T. (2010) · Food & Function · doi:10.1039/c0fo00103a · Cited by 605
Metadata
- Authors
- Reaven, G.
- Venue
- Recent Progress in Hormone Research
- Publisher
- The Endocrine Society
- Published
- 2004-01-01
- Volume
- 59
- Issue
- 1
- Pages
- 207-223
- ISSN
- 0079-9963 (ISSN-L)
- OpenAlex
- W2146175913
- Cited by
- 348
- References
- 27
- FWCI
- 16.22
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.